KBP-COVID-19
KBP-COVID-19 Uses, Dosage, Side Effects, Food Interaction and all others data.
The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690).
| Trade Name | KBP-COVID-19 |
| Generic | KBP-COVID-19 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here KBP-COVID-19
